Artiva Biotherapeutics' AlloNK Shows 71% Response in Refractory RA, Clears FDA Path to Phase 3
Event summary
- AlloNK (AB-101) demonstrated 71% ACR50 response in refractory RA patients with six months of follow-up in Phase 2a trial.
- FDA aligned on a single Phase 3 trial design for AlloNK plus rituximab vs. rituximab alone in refractory RA.
- Artiva plans to initiate Phase 3 trial in H2 2026 with ACR50 at six months as primary endpoint.
- Multiple EULAR 2026 presentations to detail AlloNK's efficacy across autoimmune diseases.
- Artiva had $86.8M in cash as of Q1 2026, expected to fund operations into Q2 2027.
The big picture
Artiva Biotherapeutics' positive Phase 2a data for AlloNK in refractory RA positions it as a potential leader in cell therapy for autoimmune diseases. The FDA's alignment on a Phase 3 trial design reduces regulatory risk and accelerates the path to market. The upcoming EULAR 2026 presentations will further validate AlloNK's mechanism of action and clinical activity across multiple autoimmune indications.
What we're watching
- Clinical Efficacy
- Whether AlloNK's 71% ACR50 response rate in refractory RA can be replicated in the Phase 3 trial.
- Regulatory Pathway
- The pace at which the FDA Phase 3 trial will proceed and its potential impact on AlloNK's market approval timeline.
- Financial Runway
- How Artiva will manage its $86.8M cash position to support operations through Q2 2027 and beyond.
Related topics